Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Dasatinib products are in shortage in Canada (1 of 14 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
A targeted cancer therapy (tyrosine kinase inhibitor) used to treat certain leukemias.
Products affected
1 / 14
In shortage since
Jan 6, 2022
Reports on file
31
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
REDDY-DASATINIB
140MG · TABLET · DR REDDY'S LABORATORIES LTD
DIN 02514796 · since Jan 6, 2022, no end estimate · Requirements related to complying with good manufacturing practices.
Resolved
TEVA-DASATINIB
80MG · TABLET · TEVA CANADA LIMITED
DIN 02478331 · ended Jun 3, 2026 · Disruption of the manufacture of the drug.
Resolved
TARO-DASATINIB
20MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02499282 · ended Mar 13, 2026 · Disruption of the manufacture of the drug.
Resolved
TARO-DASATINIB
50MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02499304 · ended Mar 13, 2026 · Disruption of the manufacture of the drug.
Resolved
TARO-DASATINIB
70MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02499312 · ended Mar 13, 2026 · Disruption of the manufacture of the drug.
Resolved
TARO-DASATINIB
80MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02499320 · ended Mar 13, 2026 · Disruption of the manufacture of the drug.
Resolved
TARO-DASATINIB
140MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02499347 · ended Mar 13, 2026 · Disruption of the manufacture of the drug.
Resolved
TARO-DASATINIB
100MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02499339 · ended Feb 27, 2026 · Disruption of the manufacture of the drug.
Resolved
APO-DASATINIB
20MG · TABLET · APOTEX INC
DIN 02470705 · ended Nov 20, 2025 · Disruption of the manufacture of the drug.
Resolved
APO-DASATINIB
50MG · TABLET · APOTEX INC
DIN 02470713 · ended Oct 9, 2025 · Disruption of the manufacture of the drug.
Resolved
TARO-DASATINIB
50MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02499304 · ended Jan 23, 2025 · Disruption of the manufacture of the drug.
Resolved
APO-DASATINIB
100MG · TABLET · APOTEX INC
DIN 02470721 · ended Sep 19, 2024 · Disruption of the manufacture of the drug.
Showing 12 of 31 reports. All reports are on file with Health Canada.
What's happening
Dasatinib is currently affected by an active shortage report filed with Health Canada by DR REDDY'S LABORATORIES LTD.
The reported cause is: requirements related to complying with good manufacturing practices. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Recent changes
No changes recorded yet.
Common questions
What is Dasatinib used for?
A targeted cancer therapy (tyrosine kinase inhibitor) used to treat certain leukemias.
When will Dasatinib be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Dasatinib in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Possible alternatives in the same class
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.